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Aims
and methods
To: (i) describe the baseline characteristics of patients in ATMOSPHERE and the changes in the planned analysis
of ATMOSPHERE resulting from the mandated discontinuation of study treatment in patients with diabetes; (ii)
compare the baseline characteristics of patients in ATMOSPHERE with those in the Prospective comparison of
Angiotensin Receptor neprilysin inhibitors with Angiotensin converting enzyme inhibitors to Determine Impact on
Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF); and (iii) compare the characteristics of patients
with and without diabetes at baseline in ATMOSPHERE.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Results A total of 7063 patients were randomized into ATMOSPHERE April 2009–April 2014 at 755 sites in 43 countries.
Their average age was 63 years and 78% were men. ATMOSPHERE patients were generally similar to those in
PARADIGM-HF although fewer had diabetes, renal dysfunction, and were treated with a mineralocorticoid receptor
antagonist. In ATMOSPHERE, patients with diabetes differed in numerous ways from those without. Patients with
diabetes were older and had worse heart failure status but a similar left ventricular ejection fraction (mean 28%);
they had a higher body mass index and more co-morbidity, especially hypertension and coronary heart disease. Mean
estimated glomerular filtration rate was slightly lower in those with diabetes compared with those without.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusion ATMOSPHERE will determine whether patients with HF and reduced ejection fraction (particularly those without
diabetes) benefit from the addition of a direct renin inhibitor to standard background therapy, including an
angiotensin-converting enzyme inhibitor, beta-blocker, and a mineralocorticoid receptor antagonist. ATMOSPHERE
will also determine whether aliskiren alone is superior to, or at least non-inferior to, enalapril.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Introduction
The Aliskiren Trial to Minimize OutcomeS in Patients with HEart
failure trial (ATMOSPHERE) was designed to make two treat-
ment comparisons, namely (i) the combination of the direct
renin inhibitor aliskiren plus enalapril with enalapril alone, and
(ii) aliskiren monotherapy with enalapril monotherapy, in a broad
spectrum of patients with heart failure and reduced ejection frac-
tion (HF-REF).1 However, as we have described elsewhere, the
premature termination of the Aliskiren Trial In Type 2 Diabetes
Using Cardio-Renal Disease Endpoints (ALTITUDE) because of
futility and safety concerns, and the subsequent finding in the
Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT)
of worse outcomes in the diabetic subgroup treated with aliskiren,
led the Clinical Trial Facilitation Group (CTFG) of the Heads of
Medicines Agencies in Europe to mandate that all individuals with
diabetes in ATMOSPHERE have study drug discontinued, even
though both ALTITUDE and ASTRONAUT studied the combi-
nation of aliskiren with an angiotensin-converting enzyme (ACE)
inhibitor or angiotensin receptor blocker (ARB) and not aliskiren
monotherapy (whereas two out of three patients in ATMOSPHERE
received either enalapril or aliskiren alone).2–6 The CTFG also
mandated that no further patients with diabetes be enrolled in
ATMOSPHERE (and that patients developing diabetes during the
trial be switched to conventional therapy). Despite the uncertainty
created by the findings in the above trials and the aforementioned
regulatory restrictions, ATMOSPHERE completed recruitment in
April 2014.
ATMOSPHERE will shortly complete follow-up as the
pre-specified number of patients with a primary endpoint has
almost accrued, even though events among patients with diabetes
occurring after the regulatory intervention described above are
not included in this total. In this paper we describe the baseline
characteristics of the patients randomized into ATMOSPHERE
as well as the various changes in the planned analysis of ATMO-
SPHERE resulting from the mandated discontinuation of study
treatment in patients with diabetes. The baseline characteristics
are compared with those of patients in the recently reported
Prospective comparison of Angiotensin Receptor neprilysin
inhibitors with Angiotensin converting enzyme inhibitors to
Determine Impact on Global Mortality and morbidity in Heart
Failure trial (PARADIGM-HF) and, in view of the regulatory con-
cerns raised, we also compare the characteristics of patients with
and without diabetes at baseline in ATMOSPHERE.7
Methods
ATMOSPHERE summary of design
and original analysis plan
The ATMOSPHERE study rationale and design has been described
in detail elsewhere.1 Briefly, ATMOSPHERE is a randomized,
double-blind, double-dummy, parallel-group, active control, three-arm,
long-term morbidity and mortality trial evaluating the efficacy and
safety of the combination of aliskiren plus enalapril in comparison
with enalapril alone, as well as evaluating aliskiren as monotherapy ..
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.. in comparison with enalapril. Patients were required to be 18 years
of age and older, have chronic symptomatic heart failure (New York
Heart Association functional class II–IV), left ventricular ejection
fraction (LVEF) ≤35% and an elevated plasma BNP or N-terminal
pro B-type natriuretic peptide (NT proBNP), as summarized in
Table 1. Patients were randomized 1:1:1 to enalapril, the combination
of enalapril plus aliskiren, or aliskiren alone. Eligible patients were
required to undergo an active run-in period of between 5weeks and
12weeks comprising exposure first to enalapril at either 10mg/day or
20mg/day depending on previous ACE inhibitor dosage, up-titrating (if
required) to 20mg/day. Patients then had aliskiren 150mg/day added
to the tolerated dose of enalapril. Patients tolerating both agents were
then randomized to enalapril 5 or 10mg twice daily to continue at
highest tolerated dose, the combination of aliskiren and enalapril with
aliskiren up-titrated to 300mg/day or aliskiren 150mg/day, up-titrated
to 300mg/day.
The original primary objectives of ATMOSPHERE were to test
whether the combination of aliskiren and enalapril is superior to
enalapril monotherapy in delaying time to the first occurrence of
cardiovascular death or hospitalization due to heart failure, and to
test whether aliskiren monotherapy is superior, or at least non-inferior,
to enalapril monotherapy using the same endpoint. The annual event
rate for this composite outcome was estimated to be 14.5% in the
control (enalapril monotherapy arm) assuming an estimated annual
drop-out rate of 4%. For superiority of the combination of enalapril
plus aliskiren over enalapril alone, the study had 82% power to detect
a 15% reduction in the primary endpoint; for superiority of aliskiren
monotherapy over enalapril monotherapy, the power was 80%. The
trial also had >80% power for non-inferiority (aliskiren vs. enalapril),
assuming a 6% difference in favour of aliskiren (and a non-inferiority
margin of 10.4% calculated using the 95–95 method with preservation
of 50% of the benefit of enalapril over placebo)
ATMOSPHERE revised analysis plan
The statistical analysis plan was amended in light of the regulatory
intervention to discontinue study drug in patients with diabetes.
The major changes are:
1 In the main efficacy analyses, in patients with diabetes, follow-up
for trial end-points will be censored on the date of the local
implementation of health authority or ethics committee requests
to stop study treatment. Patients with renal impairment in France
and Ireland and all patients from Venezuela will also be censored
in a similar fashion because of specific study drug discontinuation
requests in those countries. Individuals with diabetes but off study
drug have been followed up as stipulated in the trial protocol and
all events reported during the total duration of follow-up (even
if occurring after mandatory discontinuation of study drug) will
be included in safety analyses. We believe that this censoring will
not introduce bias as stopping of treatment was not determined
by either the investigator or sponsor and was not related to a
specific study treatment or decided with knowledge of treatment
effect (or any other unblinded data) in these patients. Censoring
is solely dependent on patient baseline characteristics (country
and diabetes/renal function) and applies to patients who had been
off treatment before to the health authority or ethics committee
requests to stop study treatment
2 Comparison of enalapril plus aliskiren with enalapril monotherapy
in patients without diabetes has been added as an additional
superiority hypothesis (Figure1). Because of the large size of the
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Table 1 Key design features of ATMOSPHERE and PARADIGM-HF
ATMOSPHERE (N= 7063) PARADIGM-HF (N= 8442)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Inclusion criteria
Age, years ≥18 ≥ 18
NYHA class II–IV II–IV
LVEF, % ≤35% ≤40% (amended to ≤35%)
Natriuretic peptides BNP ≥150 pg/mL (NT-proBNP ≥ 600 pg/mL)
or BNP≥100 pg/mL (NT-proBNP ≥ 400 pg/mL) if
unplanned hospitalization for HF within the last
12months
BNP ≥150 pg/mL (NT-proBNP ≥600 pg/mL)
or BNP ≥100 pg/mL (NT-proBNP ≥400 pg/mL) if
unplanned hospitalization for HF within the
last 12months
Background therapy
ACE inhibitor/ARB Treatment with an ACE inhibitor at a stable dose
(equivalent to at least enalapril 10mg daily)
Treatment with an ACE inhibitor or an ARB at a stable
dose (equivalent to at least enalapril 10mg daily)
Beta-blocker Treatment with a beta-blocker (unless not tolerated or
contraindicated)
Treatment with a beta-blocker (unless not tolerated or
contraindicated)
MRA Use of both an ARB and a MRA prohibited. Either one
could be prescribed but only with extreme caution
and very rigorous safety monitoring. Requirement to
warn patient about risks of renal dysfunction and
hyperkalaemia
Protocol amended to state that a MRA should be
considered in all patients, taking account of renal
function, serum potassium, and tolerability
Exclusion criteria
eGFR, ml/min.1.73m2 <40 (screening), <35 (run-in/randomization)† <30 (screening), <30 (run-in/randomization)†
Systolic blood pressure,
mmHg
<95 (screening), <90 (run-in/randomization) or
symptomatic hypotension
<100 (screening) <95 (run-in/randomization) or
symptomatic hypotension
Potassium, mmol/L ≥5.0 (screening), ≥5.2 (run-in/randomization) >5.2 (screening), >5.4 (run-in/randomization)
Run-in*
First period Enalapril 10mg bid** Enalapril 10mg bid
Second period Enalapril 10mg bid plus aliskiren 150mg qd** LCZ696 200mg bid
Comparison Enalapril 10mg bid**
Aliskiren 300mg/day+ enalapril 10mg bid**
Aliskiren 300mg/day
Enalapril 10mg bid
LCZ696 200mg bid
Recruitment period 2009–2014 2009–2012‡
ATMOSPHERE, aliskiren trial to minimize outcomes in patients with heart failure trial; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; eGFR,
estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; PARADIGM-HF,
prospective comparison of angiotensin receptor neprilysin inhibitors with angiotensin converting enzyme inhibitors to determine impact on global mortality and morbidity in
heart failure trial.
*Target doses patients must achieve and tolerate.
†Or a decrease of eGFR of more than 25% between screening and randomization visit (amended to 35% in PARADIGM-HF).
‡The last patient entered the run-in in 2012 but was randomized in 2013.
**Up to 1/5 patients could be enrolled in a low-dose stratum (enalapril 5mg bid).
subgroup of patients without diabetes, significant imbalances in
baseline characteristics are not expected between the treatment
groups. Should such imbalances occur, sensitivity analyses adjusting
the treatment effect for the appropriate covariates will be carried
out.
3 Of the two original secondary endpoints, only change from baseline
to 12months in the clinical summary score of the Kansas City Car-
diomyopathy Questionnaire (KCCQ) has been retained (change
in BNP level from baseline to 4months has been removed as it
was felt that this surrogate endpoint was not considered clinically
important).8
A gate-keeping procedure that combines hierarchical and simul-
taneous testing based upon Bonferroni inequality will be used to
ensure control of the type I error rate for the primary and secondary
endpoints.9 This multiple testing procedure is illustrated in Figure1.
The revised power calculations for superiority are shown in Table 2.
The power for the primary analyses is largely preserved and the ..
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. power to show a mean difference of 2 points in the KCCQ secondary
endpoint is 94%.
Comparison of ATMOSPHERE and PARADIGM-HF
The present report describes the baseline characteristics of the
patients randomized in ATMOSPHERE following the screening and
open-label run-in period of the study. These characteristics are
compared with the baseline findings at the same time-point in
PARADIGM-HF, which also had a sequential, two-treatment, active
run-in period.10,11 PARADIGM-HF was similar, but not identical,
in design to ATMOSPHERE, as illustrated in Table 1 and discussed
later.
Comparison of patients with and without diabetes
in ATMOSPHERE
A breakdown of patient characteristics according to diabetes status
at baseline is also reported, in view of the specific concerns raised in
© 2015 The Authors
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Figure 1 Graphical illustration and definition of the testing strategy. The primary null hypotheses are denoted by: H1 (superiority of
combination enalapril plus aliskiren vs. enalapril alone in the entire study population); H′1 (superiority of combination vs. enalapril in patients
without diabetes); H2 (superiority of aliskiren monotherapy vs. enalapril monotherapy); and H3 (non-inferiority of aliskiren monotherapy
vs. enalapril). The key secondary hypotheses are designated H41 and H42 (superiority of combination therapy vs. enalapril and aliskiren
monotherapy vs. enalapril for the Kansas City Cardiomyopathy Questionnaire clinical summary score). The initial allocation of significance
levels are 𝛼/4, 𝛼/4, 𝛼/2, 0, 0, 0 for H1, H′1, H3, H2, H41, and H42, respectively. If a hypothesis can be rejected, the relocation of its significance
level to one of the other hypotheses is as shown in the Figure. The relocation of the significance level and the specified portion of the significance
level (as a fraction) is shown by the arrows in the Figure. The sequentially rejective multiple test procedure is completed when no hypothesis
can be rejected anymore. The significance levels are rounded to four decimals based on 𝛼 = 0.025. The final significance level presented will
also be adjusted for interim analyses. To illustrate this further, if the initial test for H′1 at the 0.0062 significance level is attained, the entire
0.0062 significance level will be relocated (carried forward) to test H1. As a consequence, the test for H1 can be made at a significance level
of 0.0124 (i.e. the relocated 0.0062 from H′1 plus the initial 0.0062 for H1). If the test for H′1 is not significant, the 0.0062 initially allocated
to H′1 is completely spent, without any carry forward to test H1. As another example, if the test for H1 is statistically significant at any stage,
15/16 of the significance level available for H1 at that stage will be relocated to H3 and 1/16 carried forward to H41. The testing procedure
will continue and be completed until no further hypothesis can be rejected.
relation to the use of aliskiren in addition to an ACE inhibitor or ARB
in patients with diabetes, and given the additional primary analysis of
trial outcomes in individuals without diabetes at baseline. In view of the
specific concerns raised in relation to the use of aliskiren in addition to
an ACE inhibitor or ARB in patients with diabetes, and the additional
primary analysis of trial outcomes in individuals without diabetes at
baseline, a breakdown of patient characteristics according to diabetes
status at baseline is also reported. Diabetes status at the time of
randomization was determined according to investigator designation
at screening plus confirmed new cases of diabetes occurring during
the run-in period.
Results
Patients were randomized into ATMOSPHERE between April 2009
and April 2014 at 755 sites in 43 countries. Key baseline variables
are summarised in Table 3. .
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. Baseline characteristics
in ATMOSPHERE and comparison
with PARADIGM-HF
The characteristics of patients in ATMOSPHERE and
PARADIGM-HF were, for the most part, very similar: most
were male, middle-aged, and Caucasian. A majority had a history
of coronary heart disease and just over one-third had a history
of atrial fibrillation. The NYHA class distribution and mean LVEF
were similar, as was the mean Kansas City Cardiomyopathy Ques-
tionnaire (KCCQ) clinical summary score. There was a very high
rate (>90%) of treatment with a beta-blocker in both trials.
There were, however, some notable differences. The propor-
tion of patients with diabetes was lower in ATMOSPHERE than in
PARADIGM-HF (28% vs. 35%), as was the proportion with a his-
tory of hypertension (62% vs. 71%), although, at randomization,
© 2015 The Authors
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Table 2 Revised power scenarios for superiority
Risk
reduction
Power (%) H1
*
(𝜶= 0.62375% one-
sided, not adjusted for
safety interim looks)
Power (%) H2
(𝜶= 1.16719%
one-sided, not adjusted
for safety interim looks)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15% 75% 82%
16.5% 85% 89%
18% 91% 94%
*For H1 risk reductions of 15.7% or larger can be detected with a power of
at least 80%. H1 refers to the primary hypothesis comparing the superiority of
the combination enalapril plus aliskiren vs. enalapril alone in the entire study
population) and H2 to the co-primary hypothesis comparing the superiority
of aliskiren monotherapy vs. enalapril monotherapy. For H3 (non-inferiority
comparison of aliskiren with enalapril), the power will remain >80% provided
there is a relative risk reduction for aliskiren compared with enalapril of at
least 6%.
systolic blood pressure was higher in ATMOSPHERE than in
PARADIGM-HF (124mmHg vs. 121mmHg), as was the propor-
tion of Asian patients.
Mean estimated glomerular filtration rate (eGFR) at randomiza-
tion was also higher in ATMOSPHERE at 74mL/min.1.73m2, com-
pared with 68mL/min.1.73m2 in PARADIGM-HF. The proportion
of patients with an eGFR <60mL/min.1.73m2 was correspondingly
smaller in ATMOSPHERE than in PARADIGM-HF (27% vs. 35%).
Median plasma NT proBNP concentration at randomiza-
tion was slightly lower in ATMOSPHERE (1467 pg/mL) than in
PARADIGM-HF (1615 pg/mL). Lastly, use of a MRA was much
lower in ATMOSPHERE (37%) compared with PARADIGM-HF
(56%).
The proportion of patients with an implantable car-
dioverter defibrillator was low overall in ATMOSPHERE (as
in PARADIGM-HF) but this varied greatly by region with a device
in 55% of ATMOSPHERE patients enrolled in North America, 34%
in Western Europe but only 6.6% in the rest of the world.
Comparison of baseline characteristics
in patients with and without diabetes
in ATMOSPHERE
There were many differences between the characteristics of
patients with and without diabetes in ATMOSPHERE (Table 4).
Patients with diabetes were older and had generally worse over-
all HF status (as judged by NYHA class, KCCQ overall summary
score, signs of heart failure, NT-proBNP concentration, regular
diuretic use, and history of HF hospitalization). Mean LVEF in indi-
viduals with diabetes was the same as in those without diabetes
(28%). Patients with diabetes had a higher body mass index and
had more co-morbidity, especially a history of hypertension (74%
vs. 57%) and coronary heart disease. Mean eGFR was slightly
lower in those with diabetes and the proportion with an eGFR
<60mL/min.1.73m2 was slightly higher compared with individuals
without diabetes. Other than diuretics, the use of HF medications
(including MRAs) was similar in patients with and without diabetes, ..
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Table 3 Baseline characteristics of patients in
ATMOSPHERE compared with those in
PARADIGM-HF
ATMOSPHERE
(N= 7063)
PARADIGM-HF
(N= 8399)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age at screening visit, years 63 64
Male sex, % 78 78
Race, %
Caucasian 66 66
Black 2 5
Asian 25 18
Other 7 11
Cause of heart failure
Ischaemic aetiology, % 56 60
NYHA functional class %
Class I 2 5
Class II 69 71
Class III 28 24
Class IV 1 1
Signs of heart failure
Rales, % 10 8
Third heart sound, % 8 9
JVP elevation, % 9 10
Peripheral oedema, % 21 21
KCCQ (points)
KCCQ mean clinical
summary score
75 73
Median NT-proBNP, at
screening visit,‡ (IQR)
pg/mL
1467
(850–2664)
1615
(888–3231)
Physiological measures
LVEF at screening visit, % 28 29
Heart rate, bpm* 72 72
SBP, mmHg
at screening visit, 127 128
at randomization visit, 124 121
Median BMI, kg/m2 27 28
Laboratory measures
Serum creatinine, μmol/L 92 99
Serum potassium, mmol/L 4.5 4.5
eGFR, mL/min.1.73m2 74 68
eGFR
<60mL/min.1.73m2, %
27 36
Medical history†
Previous heart failure
hospitalization, %
60 63
Hypertension, % 62 71
Stable angina pectoris, % 19 20
Unstable angina pectoris, % 11 12
Myocardial infarction, n (%) 41 43
Percutaneous coronary
intervention, %
20 21
Coronary artery bypass
graft, %
14 16
Atrial fibrillation based on
history, %
34 37
© 2015 The Authors
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Table 3 Continued
ATMOSPHERE
(N= 7063)
PARADIGM-HF
(N= 8399)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Atrial fibrillation based on
ECG
23 25
Diabetes mellitus, % 28 35
Stroke, % 7 9
Current smoker, % 13 14
ECG findings
Left bundle branch block
(%)
21 20
QRS duration, ms 117 117
Pre-trial use of ACE
inhibitor/ARB
Previous use of ACE
inhibitor at screening
visit, %
100 78
Previous use of ARB at
screening visit, %
2 23
Pharmacological treatment
Diuretic use, % 80 80
Beta-blocker, % 92 93
MRA, % 37 56
Digoxin, % 32 30
Anticoagulant, % 30 32
Aspirin, % 51 52
Any antiplatelet agent, % 55 56
Lipid lowering, % 52 56
Devices for HF at screening
CRT, % 6 7
ICD, % 15 15
All values are from the randomization visit unless otherwise stated. For
NT-proBNP values are shown as median and 25%/75% interquartile ranges. Per-
centages reported are those with available data. Value at randomization visit is
the last non-missing value at or before the randomization visit. Percentages may
not total 100 because of rounding.
ATMOSPHERE, aliskiren trial to minimize outcomes in patients with heart
failure trial; ACE, angiotensin converting enzyme; ARB, angiotensin receptor
blocker; BMI, body mass index; CRT, cardiac resynchronization therapy; ECG,
electrocardiogram; eGFR, estimated glomerular filtration rate; ICD, implantable
cardioverter defibrillator; IQR, interquartile range; JVP, jugular venous pres-
sure; KCCQ, Kansas City Cardiomyopathy Questionnaire; MRA, mineralocor-
ticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic pep-
tide; PARADIGM-HF, prospective comparison of angiotensin receptor neprilysin
inhibitors with angiotensin converting enzyme inhibitors to determine impact on
global mortality and morbidity in heart failure trial; SBP, systolic blood pressure.
*Atrial fibrillation and diabetes mellitus are at randomization. All other medical
history variables are from the screening visit except history of atrial fibrillation
and diabetes mellitus.
†Measured as pulse rate.
‡NT pro BNP measurements were available in 5924 patients in ATMOSPHERE.
although treatments for coronary heart disease (anti-platelet and
lipid-lowering therapy) were used more frequently in subjects with
diabetes.
Discussion
The mandate by the CTFG to stop study treatment in patients
with diabetes created a number of problems for ATMOSPHERE.
These included the effort required of investigators to identify and ..
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Table 4 Baseline characteristics of patients in
ATMOSPHERE according to baseline diabetes status
ATMOSPHERE
Diabetes status
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Yes (n= 1958) No (n= 5105)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age at screening, years 65 63
Male sex, % 78 78
Race, %
Caucasian 68 65
Black 1 2
Asian 25 25
Other 6 7
Cause of heart failure
Ischaemic aetiology, % 67 52
NYHA functional class, %
Class I 2 3
Class II 67 70
Class III 30 27
Class IV 1 1
Signs of heart failure
Rales, % 12 9
Third heart sound, % 8 8
JVP elevation, % 9 9
Peripheral oedema, % 26 19
KCCQ, points
KCCQ mean clinical summary
score
72 76
Median NT-proBNP (IQR) at
screening,‡ pg/mL
1425
(796–2558)
1494
(878–2735)
Physiological measures
LVEF at screening visit, % 29 28
Heart rate, bpm† 73 71
SBP, mmHg
At screening visit, 129 126
At randomization visit, 126 123
Median BMI, kg/m2 28 26
Laboratory measures
Serum creatinine, μmol/L 93 92
Serum potassium, mmol/L 4.5 4.5
eGFR, mL/min.1.73m2 73 74
eGFR <60mL/min/1.73m2, % 29 26
Medical history*
Previous HF hospitalization, % 65 58
Hypertension, % 74 57
Stable angina pectoris, % 22 17
Unstable angina pectoris, % 14 10
Myocardial infarction, n (%) 48 38
Percutaneous coronary
intervention (%)
24 18
Coronary artery bypass
graft, %
20 12
Atrial fibrillation based on
history, %
33 35
Atrial fibrillation based on
ECG
22 24
Stroke, % 8 7
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Table 4 Continued
ATMOSPHERE
Diabetes status
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Yes (n= 1958) No (n= 5105)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Current smoker, % 11 14
ECG findings
Left bundle branch block, % 21 21
QRS duration, ms 116 117
Pre-trial use of ACE
inhibitor/ARB
Previous use of ACE inhibitor
at screening visit, %
100 100
Previous use of ARB at
screening visit, %
4 2
Pharmacological treatment
Diuretic use, % 86 78
Beta-blocker, % 92 92
MRA, % 36 37
Digoxin, % 32 32
Anticoagulant, % 30 31
Aspirin, % 57 49
Any antiplatelet agent, % 62 53
Lipid lowering, % 63 48
Devices for HF at screening
CRT, % 6.5 5.2
ICD, % 16 15
All values are from the randomization visit unless otherwise stated. Percentages
reported are those with available data. Randomization visit is the last non-missing
scheduled visit at or before visit 4. Percentages may not total 100 because of
rounding. For NT-proBNP, values are shown as median and 25%/75% interquar-
tile ranges
ATMOSPHERE, aliskiren trial to minimize outcomes in patients with heart
failure trial; ACE, angiotensin converting enzyme; ARB, angiotensin receptor
blocker; BMI, body mass index; CRT, cardiac resynchronization therapy; ECG,
electrocardiogram; eGFR, estimated glomerular filtration rate; ICD, implantable
cardioverter defibrillator; IQR, interquartile range; JVP, jugular venous pres-
sure; KCCQ, Kansas City Cardiomyopathy Questionnaire; MRA, mineralocor-
ticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic pep-
tide; PARADIGM-HF, prospective comparison of angiotensin receptor neprilysin
inhibitors with angiotensin converting enzyme inhibitors to determine impact on
global mortality and morbidity in heart failure trial; SBP, systolic blood pressure.
*Atrial fibrillation and diabetes mellitus are at randomization. All other medical
history variables are from the screening visit except history of atrial fibrillation
and diabetes mellitus.
†Measured as pulse rate.
‡NT-proBNP measurements were available in 5924 patients in ATMOSPHERE.
contact relevant patients and arrange for return of study drug as
well as prescription of alternative therapy. These investigators and
patients also had to be persuaded as to the value of continuing
follow-up after the study drug was discontinued. The exclusion
of new patients with diabetes and the generally negative publicity
surrounding aliskiren led to prolongation of the trial recruitment
period. The protocol and statistical analysis plan had to be amended
to censor the follow-up of patients with diabetes for the primary
and other efficacy endpoints on the date of submission of the pro-
tocol amendment or earlier in accordance with country-specific
regulatory requirements. As around 30% of patients recruited at
the time of this amendment had diabetes, and because diabetes ..
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.. increases cardiovascular risk, loss of follow-up time in these indi-
viduals (and exclusion of new patients with diabetes) resulted in
slower accrual of the target number of patients with a primary
endpoint, i.e. only patients without diabetes could contribute to
the pre-specified number of events after the protocol amendment
and censoring. The combination of a prolonged recruitment period
and longer than anticipated follow-up also resulted in ‘investiga-
tor fatigue’ which added to the earlier complexity of re-consenting
patients after the findings of ALTITUDE and again after the results
of ASTRONAUT. Despite these hurdles, ATMOSPHERE is nearing
completion.
The patients enrolled in ATMOSPHERE are similar to those in
the largest and most recent trial in HF-REF (i.e. PARADIGM-HF).
This is not surprising as the two study protocols were very similar
in design, although not identical (Table 1). These small differences
in design and regulatory intervention in ATMOSPHERE led to
some differences in the patients randomized in the two trials.
The exclusion of new patients with diabetes part way through
ATMOSPHERE reduced the overall proportion of patients with
diabetes (28% in ATMOSPHERE vs. 35% in PARADIGM-HF) and
this presumably mainly accounts for the difference in proportion
of patients with a history of hypertension (62% vs. 71%), given
the striking difference in prevalence of hypertension between
patients with and without diabetes (74% vs. 57%). ATMOSPHERE
also had a higher eGFR threshold for randomization (≥35 com-
pared with ≥30mL/min.1.73m2 in PARADIGM-HF) explaining
the higher average eGFR and smaller proportion of patients with
an eGFR <60mL/min.1.73m2 in ATMOSPHERE (27%) compared
with PARADIGM-HF (36%). Median NT-proBNP concentration at
randomization was slightly lower in ATMOSPHERE (1467 pg/mL)
than in PARADIGM-HF (1615 pg/mL), an observation that is
likely largely explained by the lower proportion of patients with
diabetes and reduced eGFR in ATMOSPHERE compared with
PARADIGM-HF. The systolic blood pressure at randomization
was higher in ATMOSPHERE than in PARADIGM-HF (124mmHg
vs. 121mmHg), despite the exclusion threshold in the latter trial
being higher (patients excluded if systolic pressure <90mmHg
in ATMOSPHERE and <95mmHg in PARADIGM-HF). This dif-
ference probably reflects the more powerful blood pressure
lowering effect of combined angiotensin and neprilysin inhibition
during the PARADIGM run-in period compared with the addition
of aliskiren (at half the full dose) to an ACE inhibitor during the
ATMOSPHERE run-in period. The other difference of note is in the
proportion of patients prescribed a MRA (56% in PARADIGM-HF
vs. 37% in ATMOSPHERE). This probably reflects the fact that
the use of MRA was encouraged in the amended PARADIGM-HF
protocol after the publication of the findings of Eplerenone in
Mild Patients Hospitalization And Survival Study in Heart Failure
(EMPHASIS-HF) while the recruitment of PARADIGM-HF was
ongoing. The ATMOSPHERE protocol did not specifically advocate
the use of MRAs and, indeed, warned of the risk of hyperkalaemia
if an MRA (or ARB) was added to study drug (which in one-third
of patients was the combination of enalapril and aliskiren). Most
of the recruitment into ATMOSPHERE had also occurred before
the demonstration of the benefit of MRAs in HF-REF patients with
mild symptoms, as shown in EMPHASIS-HF, and the corresponding
© 2015 The Authors
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change in guidelines (the bulk of patients in PARADIGM-HF were
recruited somewhat later than those in ATMOSPHERE).12–14
Evaluation of efficacy and safety in patients taking an MRA will
clearly be a key aspect of the analysis of the results of ATMO-
SPHERE, especially in patients randomized to dual treatment with
enalapril plus aliskiren (i.e. those receiving ‘triple therapy’). The
large subset of patients in ATMOSPHERE treated with a MRA
means that such analyses should have reasonable statistical power.
Overall, the patients in ATMOSPHERE are largely representative
of contemporary ambulatory patients with chronic HF-REF and
are well treated pharmacologically, compared with historical trials.
However, patients with diabetes are somewhat under-represented
(for the reasons described earlier) and MRA use is not as high
as would probably now be the case following recent guideline
updates.13,14 Use of devices, particularly implanted cardioverter
defibrillators, was low in ATMOSPHERE, but that was also the
case in PARADIGM-HF and in the recent Systolic Heart failure
treatment with the If inhibitor ivabradine Trial (SHIFT), probably
reflecting the high proportion of patients enrolled outside the
USA and Western Europe.15 More than half of patients enrolled
in North America and just over one third of those recruited in
Western Europe had an implantable cardioverter defibrillator at
baseline compared with less than 7% elsewhere in the world.
The differences between patients with and without diabetes in
ATMOSPHERE were similar to those in previous studies which
have consistently shown a worse overall HF status in patients
with diabetes, despite, paradoxically, a similar or higher average
LVEF.16 Similarly, comorbidity was more common in patients with
diabetes, although in ATMOSPHERE the higher prevalence of
renal dysfunction in patients with diabetes may have been less
pronounced than in previous studies because of the trial-specific
lower eGFR exclusion criterion.
The regulatory concerns about the safety of aliskiren used
in combination with an ACE inhibitor or ARB in patients with
diabetes and the subgroup analysis of ASTRONAUT have also
led us to amend the statistical analysis plan for ATMOSPHERE.
While the effect of aliskiren in ASTRONAUT was neutral overall,
the subgroup of patients with diabetes treated with aliskiren
added to an ACE inhibitor or ARB did worse than those with
added placebo; the converse was also observed (i.e. patients
without diabetes appeared to do better with aliskiren). Indeed,
among patients without diabetes there were nominally statistically
significant reductions in the risk of the composite outcome of
cardiovascular death or HF hospitalization (HR 0.80, 95% CI
0.61–0.94) and all-cause death (HR 0.69, 95% CI 0.50–0.94) at
12months in those treated with aliskiren, compared with placebo.
For this reason, we added a third primary superiority hypothesis
(i.e. that combination enalapril/aliskiren therapy will be superior to
enalapril monotherapy in patients without diabetes; Figure 1).
While we have randomized 1958 patients with diabetes, and
although these patients are at higher risk of adverse clinical out-
comes, follow-up for analysis of the effect of treatment will be trun-
cated and we have three separate treatment groups. Consequently,
we will not have sufficient power to make definitive statements
about the efficacy and safety of aliskiren in patients with diabetes.
However, this is a question of limited clinical interest at present ..
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.. given the current prohibition of use of aliskiren in combination with
an ACE inhibitor or ARB in patients with diabetes.
We have not mentioned the potential results of ATMOSPHERE
because at this stage any such discussion would be purely spec-
ulative and would need to cover a large number of possible
outcomes. What is clear, however, is that the recent findings of
PARADIGM-HF have ‘raised the bar’ with respect to the benefit
of what any alternative treatment would need to exhibit to change
practice.
In summary, the patients enrolled in ATMOSPHERE are
similar to those in the largest and most recent trial in HF-REF (i.e.
PARADIGM-HF) and, overall, they are largely representative of
contemporary ambulatory patients with chronic HF-REF and are
well treated pharmacologically, compared with historical trials.11
ATMOSPHERE will determine whether patients with HF-REF
(particularly those without diabetes) benefit clinically from the
addition of a direct renin inhibitor to standard background therapy,
including an ACE inhibitor and beta-blocker, and in many patients a
MRA. ATMOSPHERE will also determine whether aliskiren alone
is superior to, or at least non-inferior to, enalapril.
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